NCT00546156 - Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

December 31, 2012

Conditions

Breast Cancer

Interventions

DRUG

Doxorubicin

Standard chemotherapy regimen

DRUG

Cyclophosphamide

Standard chemotherapy regimen

DRUG

Paclitaxel

Standard chemotherapy regimen

DRUG

Bevacizumab

One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.

Trial Locations (4)

Massachusetts General Hospital, Boston

Dana-Farber Cancer Institute, Boston

Dana-Farber at Faulkner Hospital, Boston

New Hampshire Oncology-Hematology PA, Hooksett